in

Stealth Bio’s SBT-272 Shows Encouraging Action In Huntington’s Disease Animal Model

Stealth BioTherapeutics Corp MITO announced the presentation of new SBT-272 preclinical data and dosing of the first subject in its Phase 1 trial of SBT-272.

  • The new data demonstrated behavioral and metabolic improvements with SBT-272 in a mouse model of Huntington’s disease. 
  • In the study, mice were treated for up to 8 weeks with daily SBT-272 and displayed significantly improved motor function than vehicle-treated mice. 
  • SBT-272-treated mice also showed improved metabolism in multiple brain regions of the diseased animals.
  • Also Read: Stealth BioTherapeutics Showcases New Nonclinical Data From Duchenne Muscular Dystrophy Program.
  • The Phase 1 trial will enroll up to 64 healthy subjects across multiple cohorts. The study will evaluate the safety and tolerability of single and multiple ascending doses of SBT-272.
  • The Company plans to initiate chronic toxicology studies in 2022. 
  • Price Action: MITO shares closed 1.21% higher at $0.70 on Wednesday.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Source: Stealth Bio’s SBT-272 Shows Encouraging Action In Huntington’s Disease Animal Model

What do you think?

4Front Ventures Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Revoland Will Be the First Blockchain Game on Huawei Cloud